Brief: Nuvation Bio Receives Approval From China's National Medical Products Administration For Taletrectinib For Patients With Advanced ROS1-Positive Non-Small Cell Lung Cancer
06/01/2025 13:46
Jan 6 (Reuters) - Nuvation Bio Inc NUVB.N :
* NUVATION BIO RECEIVES APPROVAL FROM CHINA’S NATIONAL
MEDICAL
PRODUCTS ADMINISTRATION FOR TALETRECTINIB FOR PATIENTS WITH
ADVANCED ROS1-POSITIVE NON-SMALL CELL LUNG CANCER
* NUVATION BIO INC - TALETRECTINIB TO BE MARKETED IN CHINA
BY
INNOVENT BIOLOGICS
Source text: urn:newsml:reuters.com:*:nBwBNVG9a
Further company coverage: NUVB.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nuvation Bio
See all newsBrief: Nuvation Bio To Expand Pivotal Phase 3 Sigma Study Of Safusidenib For Idh1-Mutant Glioma To Six European Countries
Brief: Nuvation Bio To Report Third Quarter 2026 Financial Results And Provide Business Update On November 4, 2026
U.S. RESEARCH ROUNDUP-Everpure, Marvell Technology, Okta
Nuvation Bio Inc. reports results for the quarter ended June 30 - Earnings Summary
Nuvation Bio Q2 revenue beats estimates on IBTROZI growth